ERBB2 and breast cancer: Bootstrapping, stratified analysis, and comparison with clinical trial data reinforced our confidence in those results and thus allowed us to identify that CDK4/6i exposure led to a different—more altered—genomic landscape of HR+/HER2- BC tumors.